The global left atrial appendage (LAA) closure device market is envisioned to garner $8,218.10 million by 2031, growing from $1,276.90 million in 2021 at a CAGR of 20.97% from 2022 to 2031.
The global Left Atrial Appendage (LAA) Closure device is implanted in the heart and is intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation. The device mechanically occludes the LAA to prevent LAA thrombus from entering the circulation of the blood in the body. LAA closure reduces the stroke risk associated with atrial fibrillation. But, it doesn’t treat the AFib itself. Left atrial appendage closure can benefit people who need heart surgery and also have atrial fibrillation. The procedure is also helpful for those who have atrial fibrillation.
The rising prevalence of atrial fibrillation is anticipated to augment the need for left atrial appendage closure devices. Atrial fibrillation was one the most prevalent atrial arrhythmia in patients suffering from congenital heart disease. Additionally, the aging population will increase atrial fibrillation disease incidences, as elderly adults are more susceptible to arrhythmia, ischemic stroke disease, and atrial fibrillation. Such factors are anticipated to drive the Left Atrial Appendage (LAA) Closure device market value.
However, the availability of alternatives and the high cost of left atrial appendage atrial closure devices may negatively impact the market expansion. Oral anticoagulation is the conventional alternative to left atrial appendage closure devices and is extensively preferred by doctors with non-valvular atrial fibrillation. The development of non-vitamin oral anticoagulants (NOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban have facilitated the use of oral anti-coagulants among patients that are susceptible to thromboembolic events in stroke management. Such factors are anticipated to restrict the Left Atrial Appendage (LAA) Closure device market growth.
The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. There were import-export restrictions laid down on major Left Atrial Appendage (LAA) Closure device-producing countries such as the United States and China, which imposed significant challenges on the market. COVID-19 virus enhances the thrombo-inflammatory cascade, which intensifies coagulation and may increase the risk of cardiac embolism in patients with AF. The limitations regarding the ICU beds during the pandemic represent a major restriction in performing heart surgeries including left atrial appendage closure procedures, thereby reducing the usage of left atrial appendage closure devices.
The key players profiled in the Left Atrial Appendage (LAA) Closure Device market report include Boston Scientific Corporation, Abbott, Lifetech Scientific, ATRICURE, INC., SentreHEART, Inc., Medical Device Business Services, Inc., Occlutech, Cardia, Inc., Johnson & Johnson Private Limited, and Lepu Medical Technology Co., Ltd.
The global Left Atrial Appendage (LAA) Closure device is implanted in the heart and is intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation. The device mechanically occludes the LAA to prevent LAA thrombus from entering the circulation of the blood in the body. LAA closure reduces the stroke risk associated with atrial fibrillation. But, it doesn’t treat the AFib itself. Left atrial appendage closure can benefit people who need heart surgery and also have atrial fibrillation. The procedure is also helpful for those who have atrial fibrillation.
The rising prevalence of atrial fibrillation is anticipated to augment the need for left atrial appendage closure devices. Atrial fibrillation was one the most prevalent atrial arrhythmia in patients suffering from congenital heart disease. Additionally, the aging population will increase atrial fibrillation disease incidences, as elderly adults are more susceptible to arrhythmia, ischemic stroke disease, and atrial fibrillation. Such factors are anticipated to drive the Left Atrial Appendage (LAA) Closure device market value.
However, the availability of alternatives and the high cost of left atrial appendage atrial closure devices may negatively impact the market expansion. Oral anticoagulation is the conventional alternative to left atrial appendage closure devices and is extensively preferred by doctors with non-valvular atrial fibrillation. The development of non-vitamin oral anticoagulants (NOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban have facilitated the use of oral anti-coagulants among patients that are susceptible to thromboembolic events in stroke management. Such factors are anticipated to restrict the Left Atrial Appendage (LAA) Closure device market growth.
The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. There were import-export restrictions laid down on major Left Atrial Appendage (LAA) Closure device-producing countries such as the United States and China, which imposed significant challenges on the market. COVID-19 virus enhances the thrombo-inflammatory cascade, which intensifies coagulation and may increase the risk of cardiac embolism in patients with AF. The limitations regarding the ICU beds during the pandemic represent a major restriction in performing heart surgeries including left atrial appendage closure procedures, thereby reducing the usage of left atrial appendage closure devices.
The key players profiled in the Left Atrial Appendage (LAA) Closure Device market report include Boston Scientific Corporation, Abbott, Lifetech Scientific, ATRICURE, INC., SentreHEART, Inc., Medical Device Business Services, Inc., Occlutech, Cardia, Inc., Johnson & Johnson Private Limited, and Lepu Medical Technology Co., Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the left atrial appendage (LAA) closure device market analysis from 2021 to 2031 to identify the prevailing left atrial appendage (LAA) closure device market opportunities.
- Market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
- An in-depth analysis of the left atrial appendage (LAA) closure device market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global left atrial appendage (LAA) closure device market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Endocardial LAA Devices
- Epicardial LAA Devices
By End Use
- Hospitals
- Ambulatory Surgery Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest Of Asia Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
Key Market Players
- sentreheart, inc.
- Boston Scientific Corporation
- AtriCure, Inc.
- Abbott Laboratories
- Occlutech
- lifetech scientific corporation
- Cardia, Inc.
- Aegis Medical Group.
- Biosense Webster, Inc.
- Johnson & Johnson Services, Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
3.7. Regulatory Guidelines
3.8. Value Chain Analysis
3.9. Market Share Analysis
3.10. Key Regulation Analysis
3.11. Patent Landscape
CHAPTER 4: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Endocardial LAA Devices
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Epicardial LAA Devices
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospitals
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Ambulatory Surgery Centers
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Product
6.2.3 North America Market size and forecast, by End Use
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Product
6.2.4.1.2 Market size and forecast, by End Use
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Product
6.2.4.2.2 Market size and forecast, by End Use
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Product
6.2.4.3.2 Market size and forecast, by End Use
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Product
6.3.3 Europe Market size and forecast, by End Use
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Product
6.3.4.1.2 Market size and forecast, by End Use
6.3.4.2 United Kingdom
6.3.4.2.1 Market size and forecast, by Product
6.3.4.2.2 Market size and forecast, by End Use
6.3.4.3 France
6.3.4.3.1 Market size and forecast, by Product
6.3.4.3.2 Market size and forecast, by End Use
6.3.4.4 Spain
6.3.4.4.1 Market size and forecast, by Product
6.3.4.4.2 Market size and forecast, by End Use
6.3.4.5 Italy
6.3.4.5.1 Market size and forecast, by Product
6.3.4.5.2 Market size and forecast, by End Use
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Product
6.3.4.6.2 Market size and forecast, by End Use
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Product
6.4.3 Asia-Pacific Market size and forecast, by End Use
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 China
6.4.4.1.1 Market size and forecast, by Product
6.4.4.1.2 Market size and forecast, by End Use
6.4.4.2 Japan
6.4.4.2.1 Market size and forecast, by Product
6.4.4.2.2 Market size and forecast, by End Use
6.4.4.3 India
6.4.4.3.1 Market size and forecast, by Product
6.4.4.3.2 Market size and forecast, by End Use
6.4.4.4 South Korea
6.4.4.4.1 Market size and forecast, by Product
6.4.4.4.2 Market size and forecast, by End Use
6.4.4.5 Australia
6.4.4.5.1 Market size and forecast, by Product
6.4.4.5.2 Market size and forecast, by End Use
6.4.4.6 Rest Of Asia Pacific
6.4.4.6.1 Market size and forecast, by Product
6.4.4.6.2 Market size and forecast, by End Use
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Product
6.5.3 LAMEA Market size and forecast, by End Use
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Product
6.5.4.1.2 Market size and forecast, by End Use
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Product
6.5.4.2.2 Market size and forecast, by End Use
6.5.4.3 UAE
6.5.4.3.1 Market size and forecast, by Product
6.5.4.3.2 Market size and forecast, by End Use
6.5.4.4 South Africa
6.5.4.4.1 Market size and forecast, by Product
6.5.4.4.2 Market size and forecast, by End Use
6.5.4.5 Rest of LAMEA
6.5.4.5.1 Market size and forecast, by Product
6.5.4.5.2 Market size and forecast, by End Use
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 sentreheart, inc.
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Boston Scientific Corporation
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 AtriCure, Inc.
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Abbott Laboratories
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Occlutech
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 lifetech scientific corporation
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Cardia, Inc.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Aegis Medical Group.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Biosense Webster, Inc.
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Johnson & Johnson Services, Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
List of Tables
Table 1. Global Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 2. Left Atrial Appendage (Laa) Closure Device Market, for Endocardial Laa Devices, by Region, 2021-2031 ($Million)
Table 3. Left Atrial Appendage (Laa) Closure Device Market for Endocardial Laa Devices, by Country, 2021-2031 ($Million)
Table 4. Left Atrial Appendage (Laa) Closure Device Market, for Epicardial Laa Devices, by Region, 2021-2031 ($Million)
Table 5. Left Atrial Appendage (Laa) Closure Device Market for Epicardial Laa Devices, by Country, 2021-2031 ($Million)
Table 6. Global Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 7. Left Atrial Appendage (Laa) Closure Device Market, for Hospitals, by Region, 2021-2031 ($Million)
Table 8. Left Atrial Appendage (Laa) Closure Device Market for Hospitals, by Country, 2021-2031 ($Million)
Table 9. Left Atrial Appendage (Laa) Closure Device Market, for Ambulatory Surgery Centers, by Region, 2021-2031 ($Million)
Table 10. Left Atrial Appendage (Laa) Closure Device Market for Ambulatory Surgery Centers, by Country, 2021-2031 ($Million)
Table 11. Left Atrial Appendage (Laa) Closure Device Market, for Others, by Region, 2021-2031 ($Million)
Table 12. Left Atrial Appendage (Laa) Closure Device Market for Others, by Country, 2021-2031 ($Million)
Table 13. Left Atrial Appendage (Laa) Closure Device Market, by Region, 2021-2031 ($Million)
Table 14. North America Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 15. North America Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 16. North America Left Atrial Appendage (Laa) Closure Device Market, by Country, 2021-2031 ($Million)
Table 17. U.S. Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 18. U.S. Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 19. Canada Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 20. Canada Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 21. Mexico Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 22. Mexico Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 23. Europe Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 24. Europe Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 25. Europe Left Atrial Appendage (Laa) Closure Device Market, by Country, 2021-2031 ($Million)
Table 26. Germany Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 27. Germany Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 28. United Kingdom Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 29. United Kingdom Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 30. France Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 31. France Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 32. Spain Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 33. Spain Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 34. Italy Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 35. Italy Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 36. Rest of Europe Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 37. Rest of Europe Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 38. Asia-Pacific Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 39. Asia-Pacific Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 40. Asia-Pacific Left Atrial Appendage (Laa) Closure Device Market, by Country, 2021-2031 ($Million)
Table 41. China Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 42. China Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 43. Japan Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 44. Japan Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 45. India Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 46. India Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 47. South Korea Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 48. South Korea Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 49. Australia Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 50. Australia Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 51. Rest of Asia-Pacific Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 52. Rest of Asia-Pacific Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 53. LAMEA Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 54. LAMEA Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 55. LAMEA Left Atrial Appendage (Laa) Closure Device Market, by Country, 2021-2031 ($Million)
Table 56. Brazil Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 57. Brazil Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 58. Saudi Arabia Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 59. Saudi Arabia Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 60. UAE Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 61. UAE Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 62. South Africa Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 63. South Africa Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 64. Rest of LAMEA Left Atrial Appendage (Laa) Closure Device Market, by Product, 2021-2031 ($Million)
Table 65. Rest of LAMEA Left Atrial Appendage (Laa) Closure Device Market, by End Use, 2021-2031 ($Million)
Table 66. Sentreheart, Inc.: Company Snapshot
Table 67. Sentreheart, Inc.: Operating Segments
Table 68. Sentreheart, Inc.: Product Portfolio
Table 69. Sentreheart, Inc.: Net Sales
Table 70. Sentreheart, Inc.: Key Strategies
Table 71. Boston Scientific Corporation: Company Snapshot
Table 72. Boston Scientific Corporation: Operating Segments
Table 73. Boston Scientific Corporation: Product Portfolio
Table 74. Boston Scientific Corporation: Net Sales
Table 75. Boston Scientific Corporation: Key Strategies
Table 76. Atricure, Inc.: Company Snapshot
Table 77. Atricure, Inc.: Operating Segments
Table 78. Atricure, Inc.: Product Portfolio
Table 79. Atricure, Inc.: Net Sales
Table 80. Atricure, Inc.: Key Strategies
Table 81. Abbott Laboratories: Company Snapshot
Table 82. Abbott Laboratories: Operating Segments
Table 83. Abbott Laboratories: Product Portfolio
Table 84. Abbott Laboratories: Net Sales
Table 85. Abbott Laboratories: Key Strategies
Table 86. Occlutech: Company Snapshot
Table 87. Occlutech: Operating Segments
Table 88. Occlutech: Product Portfolio
Table 89. Occlutech: Net Sales
Table 90. Occlutech: Key Strategies
Table 91. Lifetech Scientific Corporation: Company Snapshot
Table 92. Lifetech Scientific Corporation: Operating Segments
Table 93. Lifetech Scientific Corporation: Product Portfolio
Table 94. Lifetech Scientific Corporation: Net Sales
Table 95. Lifetech Scientific Corporation: Key Strategies
Table 96. Cardia, Inc.: Company Snapshot
Table 97. Cardia, Inc.: Operating Segments
Table 98. Cardia, Inc.: Product Portfolio
Table 99. Cardia, Inc.: Net Sales
Table 100. Cardia, Inc.: Key Strategies
Table 101. Aegis Medical Group.: Company Snapshot
Table 102. Aegis Medical Group.: Operating Segments
Table 103. Aegis Medical Group.: Product Portfolio
Table 104. Aegis Medical Group.: Net Sales
Table 105. Aegis Medical Group.: Key Strategies
Table 106. Biosense Webster, Inc.: Company Snapshot
Table 107. Biosense Webster, Inc.: Operating Segments
Table 108. Biosense Webster, Inc.: Product Portfolio
Table 109. Biosense Webster, Inc.: Net Sales
Table 110. Biosense Webster, Inc.: Key Strategies
Table 111. Johnson & Johnson Services, Inc.: Company Snapshot
Table 112. Johnson & Johnson Services, Inc.: Operating Segments
Table 113. Johnson & Johnson Services, Inc.: Product Portfolio
Table 114. Johnson & Johnson Services, Inc.: Net Sales
Table 115. Johnson & Johnson Services, Inc.: Key Strategies
List of Figures
Figure 1. Left Atrial Appendage (Laa) Closure Device Market Segmentation
Figure 2. Left Atrial Appendage (Laa) Closure Device Market, 2021-2031
Figure 3. Left Atrial Appendage (Laa) Closure Device Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Left Atrial Appendage (Laa) Closure Device Mark.:Drivers, Restraints and Opportunities
Figure 12. Regulatory Guidelines
Figure 13. Value Chain Analysis
Figure 14. Market Share Analysis
Figure 15. Key Regulation Analysis
Figure 16. Patent Analysis by Company
Figure 17. Patent Analysis by Country
Figure 18. Left Atrial Appendage (Laa) Closure Device Market, By Product, 2021(%)
Figure 19. Comparative Share Analysis of Endocardial Laa Devices Left Atrial Appendage (Laa) Closure Device Market, 2021-2031(%)
Figure 20. Comparative Share Analysis of Epicardial Laa Devices Left Atrial Appendage (Laa) Closure Device Market, 2021-2031(%)
Figure 21. Left Atrial Appendage (Laa) Closure Device Market, By End Use, 2021(%)
Figure 22. Comparative Share Analysis of Hospitals Left Atrial Appendage (Laa) Closure Device Market, 2021-2031(%)
Figure 23. Comparative Share Analysis of Ambulatory Surgery Centers Left Atrial Appendage (Laa) Closure Device Market, 2021-2031(%)
Figure 24. Comparative Share Analysis of Others Left Atrial Appendage (Laa) Closure Device Market, 2021-2031(%)
Figure 25. Left Atrial Appendage (Laa) Closure Device Market by Region, 2021
Figure 26. U.S. Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 27. Canada Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 28. Mexico Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 29. Germany Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 30. United Kingdom Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 31. France Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 32. Spain Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 33. Italy Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 34. Rest of Europe Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 35. China Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 36. Japan Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 37. India Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 38. South Korea Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 39. Australia Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 40. Rest of Asia-Pacific Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 41. Brazil Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 42. Saudi Arabia Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 43. Uae Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 44. South Africa Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 45. Rest of LAMEA Left Atrial Appendage (Laa) Closure Device Market, 2021-2031($Million)
Figure 46. Top Winning Strategies, by Year
Figure 47. Top Winning Strategies, by Development
Figure 48. Top Winning Strategies, by Company
Figure 49. Product Mapping of Top 10 Players
Figure 50. Competitive Dashboard
Figure 51. Competitive Heatmap of Top 10 Key Players
Figure 52. Sentreheart, Inc.: Net Sales, ($Million)
Figure 53. Boston Scientific Corporatio.: Net Sales, ($Million)
Figure 54. Atricure, Inc.: Net Sales, ($Million)
Figure 55. Abbott Laboratorie.: Net Sales, ($Million)
Figure 56. Occlutec.: Net Sales, ($Million)
Figure 57. Lifetech Scientific Corporatio.: Net Sales, ($Million)
Figure 58. Cardia, Inc.: Net Sales, ($Million)
Figure 59. Aegis Medical Group.: Net Sales, ($Million)
Figure 60. Biosense Webster, Inc.: Net Sales, ($Million)
Figure 61. Johnson & Johnson Services, Inc.: Net Sales, ($Million)
Executive Summary
According to the report, “Left Atrial Appendage (LAA) Closure Device Market," the left atrial appendage closure device market size was valued at $1.3 billion in 2021 and is estimated to reach $8.2 billion by 2031, growing at a CAGR of 21% from 2022 to 2031.Left atrial appendage (LAA) closure devices are implantable cardiac devices that are placed in the left atrial appendage for preventing strokes and heart blockages in patients suffering from atrial fibrillation and blockages. Depending on the device, they may be inserted percutaneously or through minimally invasive or open surgery. In individuals with non-valvular atrial fibrillation, LAA devices are implanted in the heart to lessen the risk of thromboembolism from the left atrial appendage (LAA). To stop LAA thrombus from entering the systemic circulation, the device mechanically occludes the LAA.
Atrial fibrillation is one of the most prevalent arrhythmias, affecting people 65 years of age and older. The older population is more prone to arrhythmia and other cardiac disorders, including atrial fibrillation due to slowly degrading health. LAA Closure Device Market have recently emerged as an effective alternative for heart stroke management in patients suffering from atrial fibrillation. This is the major factor estimated to propel the left atrial appendage closure device market growth over the upcoming years.
The high cost of LAA closure device is expected to limit market growth in the coming years. As a result of ongoing technological advancement and the incorporation of modern technology, the overall cost of the LAA device is increasing. As a result, customers are opting for alternative methods, which is likely to impede the growth of the global left atrial appendage closure device market trends.
Rising awareness about the presence of technologically advanced medical devices like Left Atrial Appendages devices and their high effectiveness in treating and managing heart diseases like heart strokes is anticipated to provide a lucrative growth of the market in the next few years. Also, the rising per capita income of people in developing countries has boosted the affordability of expensive healthcare facilities. Along with it, government-regulated health schemes and health insurance coverages provided to people in developing countries are further projected to generate huge revenue. These factors are anticipated to increase the left atrial appendage closure device market share over the coming years.
The global Left Atrial Appendage (LAA) Closure Device market share is segmented based on product, end-use, and region. By product, it is classified into epicardial LAA closure devices and endocardial LAA closure devices. By end-use industry, it is classified into hospitals, ambulatory surgery centers, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in the LAA closure device industry report include Boston Scientific Corporation, Abbott, Lifetech Scientific, ATRICURE, INC., SentreHEART, Inc., Medical Device Business Services, Inc., Occlutech, Cardia, Inc., Johnson & Johnson Private Limited, and Lepu Medical Technology Co., Ltd.
The report offers a comprehensive analysis of the global Left Atrial Appendage (LAA) Closure Device market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market. The report also sheds light on the present scenario and upcoming trends & developments that are contributing to the growth of the market. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and the emergence of substitutes in the market.
Impact of Covid-19 on the Global Left Atrial Appendage (LAA) Closure Device Industry
The COVID-19 pandemic has had a negative impact on the growth of the left atrial appendage (LAA) closure device market. Due to rapidly increasing cases of infected patients, healthcare professionals prevented patients, other than COVID infected, to visit hospitals in order to prevent viral transmission.Also, many private clinics were not accepting any patient visits due to the non-availability of healthcare professionals. This factor also impeded the market growth in the pandemic time period.
Key Findings of the Study
- Based on Product, the Endocardial sub-segment emerged as the global leader in 2021 and is anticipated to be the dominating sub-segment during the forecast period.
- Based on the end-use industry, the hospital sub-segment is predicted to be dominating in the market in the upcoming years.
- Based on region, the Asia-Pacific market registered to be the fastest growing in 2022-2032, and North America is projected to be the dominating region during the forecast period.
Companies Mentioned
- sentreheart, inc.
- Boston Scientific Corporation
- AtriCure, Inc.
- Abbott Laboratories
- Occlutech
- lifetech scientific corporation
- Cardia, Inc.
- Aegis Medical Group.
- Biosense Webster, Inc.
- Johnson & Johnson Services, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
